| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 110,734 | 121,169 | 129,063 | 60,536 |
| Trade and other receivables, net | 6,867 | 17,763 | 11,801 | 11,864 |
| Inventories | 8,066 | 6,169 | 7,884 | 8,125 |
| Prepaid expenses and other current assets | 4,516 | 4,168 | 2,925 | 1,196 |
| Total current assets | 130,183 | 149,269 | 151,673 | 81,721 |
| Property and equipment, net | 3,839 | 3,893 | 3,918 | 3,858 |
| Right-of-use assets, net | 4,468 | 4,621 | 4,769 | 4,911 |
| Other non-current assets | 2,635 | 2,642 | 3,199 | 3,208 |
| Total assets | 141,125 | 160,425 | 163,559 | 93,698 |
| Accounts payable | 11,889 | 29,862 | 10,865 | 11,951 |
| Accrued expenses | 3,449 | 5,029 | 5,128 | 5,001 |
| Lease liabilities, current | 662 | 631 | 601 | 570 |
| Deferred revenue, current | 1,092 | 1,092 | 1,092 | 1,092 |
| Liability related to the sale of future revenue, current | 1,000 | 1,000 | 1,000 | 1,000 |
| Royalty obligations, current | NaN | 0 | 561 | 364 |
| Loans payable, current | 13,661 | 9,994 | 6,327 | 3,177 |
| Total current liabilities | 31,753 | 47,608 | 25,574 | 23,155 |
| Notes payable, net | 25,099 | 27,519 | 29,940 | 31,843 |
| Royalty obligations, net | 26,914 | 25,941 | 23,948 | 22,711 |
| Liability related to the sale of future revenue, net | 62,083 | 62,023 | 61,977 | 61,924 |
| Lease liabilities | 4,159 | 4,337 | 4,508 | 4,668 |
| Deferred revenue, net of current portion | 19,118 | 19,390 | 19,663 | 19,935 |
| Other non-current liabilities | 6,053 | 7,269 | 2,058 | 2,052 |
| Total liabilities | 175,179 | 194,087 | 167,668 | 166,288 |
| Common stock, 0.001 par value. authorized 250,000,000 shares 124,284,542 and 122,044,299 shares issued and outstanding at march31, 2026 and december31, 2025, respectively | 124 | 122 | 121 | 99 |
| Additional paid-in capital | 420,877 | 413,214 | 410,908 | 327,003 |
| Accumulated deficit | -455,055 | -446,998 | -415,138 | -399,692 |
| Total stockholders deficit | -34,054 | -33,662 | -4,109 | -72,590 |
| Total liabilities and stockholders deficit | 141,125 | 160,425 | 163,559 | 93,698 |
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)